pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Vidaza
drug · small molecule
save

azacitidine

Phase 2updated 3mo ago
by Bristol-Myers Squibb Co🔗 ChEMBL
Phase 2
community read0 votes

🐶 often sniffed alongside

top 8
  • drugOnureg21 co-mentions · 9 sources
  • tagApproval12 co-mentions · 3 sources
  • tagSmall Molecule8 co-mentions · 4 sources
  • tagAML7 co-mentions · 2 sources
  • tagOncology3 co-mentions · 2 sources
  • tagDrug Shortage3 co-mentions · 3 sources
  • tagPulmonology2 co-mentions · 1 sources
  • drugivosidenib2 co-mentions · 1 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 49 investigational indications.

targets

DNA (cytosine-5)-methyltransferase 1DNA (cytosine-5)-methyltransferase 3A

all catalysts(0)

nothing on the calendar yet

Trials studying azacitidine

  • phase2Pacritinib in CMMLrecruitingn=26
  • phase2Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemiacompletedn=36
  • phase3A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)recruitingn=660
  • phase1Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemiarecruitingn=24
  • phase1Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcomaactive not recruitingn=21
  • phase1A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)recruitingn=24
  • phase2Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLrecruitingn=160
  • phase2Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemiaactive not recruitingn=11
more trials →

News(1)

  • Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AML
    Courtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.
    onclive · 2mo ago
brand
Vidaza
trade names
Azacitidine, Azacitidine accord, Azacitidine betapharm, Azacitidine celgene, Azacitidine kabi, Azacitidine mylan
generic
azacitidine
MOA
DNA (cytosine-5)-methyltransferase 1 inhibitor; DNA (cytosine-5)-methyltransferase 3A inhibitor
indication
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 38m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?